Veracyte, Inc.
VCYT
$58.89
$2.133.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.91% | 16.01% | 16.41% | 19.91% | 23.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.91% | 16.01% | 16.41% | 19.91% | 23.42% |
| Cost of Revenue | 6.90% | 5.61% | 21.77% | 20.71% | 21.22% |
| Gross Profit | 21.38% | 20.89% | 14.19% | 19.56% | 24.42% |
| SG&A Expenses | 2.24% | 10.28% | 3.28% | 7.55% | 8.15% |
| Depreciation & Amortization | -8.13% | -11.42% | -15.00% | -19.85% | -23.77% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.17% | 6.63% | 7.74% | 10.78% | 12.03% |
| Operating Income | 194.02% | 199.60% | 360.15% | 3,482.40% | 331.10% |
| Income Before Tax | 158.69% | 164.92% | 479.51% | 152.87% | 149.81% |
| Income Tax Expenses | 34.61% | 15.07% | -36.83% | 451.20% | 190.19% |
| Earnings from Continuing Operations | 166.31% | 174.89% | 427.11% | 148.73% | 148.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 166.31% | 174.89% | 427.11% | 148.73% | 148.48% |
| EBIT | 194.02% | 199.60% | 360.15% | 3,482.40% | 331.10% |
| EBITDA | 104.04% | 91.33% | 107.43% | 132.86% | 281.33% |
| EPS Basic | 159.69% | 168.82% | 375.89% | 145.78% | 145.78% |
| Normalized Basic EPS | 154.38% | 157.00% | 131.59% | 274.82% | 1,385.77% |
| EPS Diluted | 161.37% | 174.97% | 349.37% | 143.73% | 143.67% |
| Normalized Diluted EPS | 155.17% | 157.98% | 132.35% | 271.34% | 1,360.87% |
| Average Basic Shares Outstanding | 2.15% | 2.75% | 3.76% | 4.65% | 5.47% |
| Average Diluted Shares Outstanding | 1.65% | 2.98% | 4.79% | 6.37% | 7.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |